Amgen stock: At EUR 383.40, Amgen stock has a USD 233.7 billion market value

Published on 10/19/2026 at 15:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen's price-to-earnings ratio is 26.81 on October 19, 2026. Amgen stock costs EUR 383.40 on October 19, 2026 at Lang & Schwarz.

Targets valuation and dates

Cantor Fitzgerald set a USD 440.00 target for Amgen on October 5, 2026.
Amgen had a USD 233.7 billion market capitalization on October 19, 2026.
Amgen stock costs EUR 383.40 at Lang & Schwarz on October 19, 2026 at 3:32 p.m. CEST.
Amgen scheduled its third-quarter 2026 earnings conference call for November 3, 2026.

Editorial-Aufnahme eines Nasdaq-Handelssaals mit großen Bildschirmen und steigenden Biotech-Sektor-Kurscharts — Amgen Inc. (ISIN US0311621009) thematisiert dieses Börsen-Editorial mit Nasdaq-Handelssaal und ansteigenden Biotech-Sektor-Kurscharts auf großen Bildschirmen, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) was trading at EUR 383.40 at Lang & Schwarz on October 19, 2026 at 3:32 p.m. CEST. Amgen carried a USD 233.7 billion market capitalization and a 26.81 price-to-earnings ratio in the latest quote.

Cantor target reaches USD 440.00

Cantor Fitzgerald raised its Amgen target from USD 400.00 to USD 440.00 in a research report dated October 5, 2026, while keeping a Neutral rating, according to MarketBeat. The target is stated in USD and is therefore separate from Amgen's euro quotation in Germany.

Nasdaq range spans USD 288.00 to USD 447.03

The Nasdaq quote stood at USD 432.35 on October 19, 2026 at 9:38 a.m. EDT. Amgen's 52-week range ran from USD 288.00 to USD 447.03, placing the US quote below its yearly high while the German euro quote remained the relevant price for this report. Trading volume was 183,453 shares against an average volume of 2,805,684 shares.

Valuation and November 3 date

The latest quote put Amgen's market capitalization at USD 233.7 billion and its price-to-earnings ratio at 26.81. The dividend yield was 0.02 percent. Amgen's investor page lists its third-quarter 2026 earnings conference call for November 3, 2026, alongside the company's second-quarter 2026 financial materials, as shown on the Amgen investor page.

Comparison with peers

Amgen (NASDAQ, USD): minus 0.03 percent, price-to-earnings ratio 26.81, market capitalization USD 233.7 billion.
Gilead Sciences (NASDAQ, USD): plus 0.42 percent, price-to-earnings ratio minus 58.67, market capitalization USD 194.5 billion.
Biogen (NASDAQ, USD): plus 1.15 percent, price-to-earnings ratio 41.35, market capitalization USD 34.8 billion.

Euro quote for German investors

Amgen's euro quotation offers a German-market view of a US biotechnology company whose Nasdaq valuation remains anchored by its USD 233.7 billion market capitalization and the USD 440.00 Cantor Fitzgerald target. The next scheduled company date is November 3, 2026.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.